InvestorsHub Logo
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

Re: DanWebzster post# 135

Wednesday, 05/02/2018 7:21:59 PM

Wednesday, May 02, 2018 7:21:59 PM

Post# of 438
OVID has two Ph2 studies to read out in 2018

Data for its treatment for Angelman's syndrome is expected Q-3/2018.

Data for rare epileptic encephalopathies (aka Dravets Syndrome) will be read out H-2/2018.

The compound for Angelmans (OV-101) is licensed from Lundbeck who took it all the way thru Ph3 for insomnia, then decided it was not commercially viable.

The compound for Dravets is licensed from Takeda ex-Asia.

Both treatments could face stiff competition if approved. Also, there is a pre-clinical gene therapy (GT) for Angelman's that could render OV-101 obsolete.

Cash runway is deep into 2019.

This a stock to stalk short on promising data read-outs.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.